Company Adial Pharmaceuticals, Inc.

Equities

ADIL

US00688A2050

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.69 ^USD	+4.97%		-11.05%	-9.14%

Apr. 22	Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder	MT
Apr. 12	Top Premarket Decliners	MT

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. The Companyâs drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder (AUD). AD04 is used for the treatment of AUD in subjects with certain target genotypes, which were identified using its companion diagnostic genetic test. AD04 is a genetically targeted, serotonin-3 receptor antagonist, a therapeutic agent for the treatment of AUD. The Companyâs AD04 also has the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders.

Number of employees: 6

Managers	Title	Age	Since
Bankole Johnson FOU	Founder	64	10-10-31
Cary Claiborne CEO	Chief Executive Officer	64	21-11-01
Joseph Truluck DFI	Director of Finance/CFO	46	16-04-30
Julien Dimastromatteo CTO	Chief Tech/Sci/R&D Officer	-	-
Tony Goodman COO	Chief Operating Officer	60	17-06-30
John Rothwell Martin LAW	General Counsel	-	-
Catherine Fratila AUD	Comptroller/Controller/Auditor	-	-
Mark H. Peikin PRN	Corporate Officer/Principal	-	19-09-30
Alex Lugovoy PRN	Corporate Officer/Principal	-	19-04-10
Schuyler Vinzant PRN	Corporate Officer/Principal	-	19-12-31

Members of the board	Title	Age	Since
Jack W. Reich LAW	General Counsel	-	20-05-18
Cary Claiborne CEO	Chief Executive Officer	64	21-11-01
Tony Goodman COO	Chief Operating Officer	60	17-06-30
J. Anderson BRD	Director/Board Member	74	15-01-31
Robertson Gilliland BRD	Director/Board Member	44	14-08-31
Bankole Johnson FOU	Founder	64	10-10-31
James Newman BRD	Director/Board Member	81	14-08-31
Kevin Schuyler CHM	Chairman	55	16-03-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,054,861	3,891,107 ( 95.96 %)	0	95.96 %

Name	Equities	%	Valuation
Armistice Capital LLC 9.559 %	159,000	9.559 %	211 470 $
Cary Claiborne 3.655 %	60,799	3.655 %	80 863 $
Manchester Capital Management LLC 2.891 %	48,097	2.891 %	63 969 $
Renaissance Technologies LLC 1.395 %	23,200	1.395 %	30 856 $
Bankole Johnson 1.261 %	20,973	1.261 %	27 894 $
G1 Execution Services LLC 0.8891 %	14,789	0.8891 %	19 669 $
James Newman 0.8137 %	13,535	0.8137 %	18 002 $
Joseph Truluck 0.6375 %	10,605	0.6375 %	14 105 $
BlackRock Institutional Trust Co. NA 0.4592 %	7,639	0.4592 %	10 160 $
Kevin Schuyler 0.3961 %	6,589	0.3961 %	8 763 $

Adial Pharmaceuticals, Inc.

4870 Sadler Road Suite 300

23060, Glen Allen

http://www.adialpharma.com

address Adial Pharmaceuticals, Inc.(ADIL)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.61 USD

Average target price

7.5 USD

Spread / Average Target

+365.84%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ADIAL PHARMACEUTICALS, INC.	-12.90%	6.53M
VERTEX PHARMACEUTICALS INCORPORATED	-2.06%	103B
REGENERON PHARMACEUTICALS, INC.	+1.87%	95.28B
ARGENX SE	+2.82%	22.15B
BIONTECH SE	-15.81%	21.02B
GENMAB A/S	-8.45%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-15.13%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+4.23%	13.68B
SAREPTA THERAPEUTICS, INC.	+32.22%	12.17B

Bio Therapeutic Drugs